2025 Individual Manufacturing Patients 
My Green Doctor
MAY 3, 2025
This isn’t just about saving the planet—it’s also about saving money, protecting patients, and strengthening our healthcare systems from the inside out. Dilating and anesthetic eye drops are routinely offered to patients in most ophthalmology clinics. Now, more than ever, they must also become champions of planetary health.
Physician's Weekly
JUNE 18, 2025
Cost-sharing interventions and patient education can help improve access to GLP-1 receptor agonists for patients with obesity, according to an abstract presented at the AACE Annual Meeting 2025. In addition, she received counseling on medication use, lifestyle changes, and nutritional goals.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
FDA Law Blog
SEPTEMBER 20, 2021
From new initiatives to facilitate faster reviews for new indications under the Split Real Time Application Review (STAR) pilot program, to bringing new meetings under PDUFA goals, to continued support for rare diseases and incorporation of the patient voice, the goals letter revealed a good number of welcome announcements.
FDA Law Blog
MAY 7, 2025
On April 14, 2025, the Seventh Circuit overturned the criminal conviction of Mark Sorensen, the owner of a durable medical equipment (DME) distributor, who had been found guilty of violating the AKS. Physicians had ultimate control and exercised independent judgment over their patients healthcare decisions. Medicare or Medicaid).
Alabama Academy of Family Physicians
FEBRUARY 19, 2025
As the 2025 legislative session swings into full gear, the Alabama Academy of Family Physicians (AAFP) has set its sights on a cadre of pivotal bills set to shape the healthcare landscape for years to come. Senate SB 43 – Patient Price Transparency Bill What’s in the Bill: Sponsored by Sen.
Physician's Weekly
JUNE 15, 2025
Patients with small fiber neuropathy and cerebellar ataxia were more likely to have anti-gliadin antibodies when a lower test threshold was used, raising the possibility of hidden gluten sensitivity in unexplained neurological conditions. of individuals vs 12.8% controls ( P = 0.017), and anti-gliadin IgG in 7.6% vs 2.6% ( P = 0.013).
FDA Law Blog
JULY 7, 2024
Laboratories struggling to understand the myriad implications of being regulated as device “manufacturers” were hopeful that additional guidance would shed light on how to apply FDA’s existing medical device regulatory framework to their operations. 803), Reporting of Corrections and Removals (21 C.F.R. § 806) and Complaint Files (21 C.F.R.
Expert insights. Personalized for you.
52 
Let's personalize your content